Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective of our study was to determine the impact of vancomycin exposure and outcomes in patients with MRSA bacteremia initially treated with vancomycin. METHODS: This was a single-center retrospective analysis of 320 patients with documented MRSA bacteremia initially treated with vancomycin from January 2005 through April 2010. Two methods of susceptibility, Etest and broth microdilution, were performed for all isolates to determine the correlation of susceptibility testing to patient outcomes. RESULTS: Among a cohort of 320 patients, more than half (52.5%) experienced vancomycin failure. Independent predictors of vancomycin failure in logistic regression included infective endocarditis (adjusted odds ratio [AOR], 4.55; 95% confidence interval [CI], 2.26-9.15), nosocomial-acquired infection (AOR, 2.19; 95% CI, 1.21-3.97), initial vancomycin trough <15 mg/L (AOR, 2.00; 95% CI, 1.25-3.22), and vancomycin minimum inhibitory concentration (MIC) >1 mg/L by Etest (AOR, 1.52; 95% CI, 1.09-2.49). With use of Classification and Regression Tree (CART) analysis, patients with vancomycin area under the curve at 24 h (AUC(24h)) to MIC ratios <421 were found to have significantly higher rates of failure, compared with patients with AUC(24h) to MIC ratios >421 (61.2% vs 48.6%; P = .038). CONCLUSIONS: In light of the high failure rates associated with this antimicrobial, optimizing the pharmacokinetic/pharmacodynamic properties of vancomycin by targeting higher trough values of 15-20 mg/L and AUC(24h)/MIC ratios ≥400 in selected patients should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489 · cited 1×
“genes encoding Panton–Valentine leukocidin, and agr group and agr function were determined using previously described methods [24, 25].”
MethodSystem, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5026-5033.2005 · Cited by 1,037
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
Cited by
Items 301–400 of 460
Review and evaluation of vancomycin dosing guidelines for obese individuals
Wong, S., Reuter, S. E., Jones, G. R. D., & STOCKER, S. L. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2098106 · Cited by 6
Yang, W., Zhang, K., Chen, Y., Fan, Y., & Zhang, J. (2024) · Antibiotics · doi:10.3390/antibiotics13060497 · Cited by 6
Torres-Sangiao, E., Pérez‐Castro, S., Fernández-Natal, M. I., Cisterna-Cáncer, R., Zapico-González, M., Fernández-Pérez, B., Ojeda-Fernández, E., Nebreda-Mayoral, T., Gozalo-Margüello, M., Foz, C. F., et al. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.036889-0 · Cited by 6
Lee, Y. W., Bae, S., Yang, E., Chung, H., Kim, E. S., Jung, J., Kim, M. J., Chong, Y. P., Kim, S., Choi, S., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab424 · Cited by 6
Application of User-Centered Codesign Principles to Address Barriers in Therapeutic Drug Monitoring
Wong, S., Davis, A., Selby, P., Khoo, R., Gwilt, I., STOCKER, S. L., Ward, M., & Reuter, S. E. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001047 · Cited by 7
Performance of processes of care and outcomes in patients with S taphylococcus aureus bacteremia
Rosa, R. M., Wawrzyniak, A. J., Sfeir, M. M., Smith, L., & Abbo, L. M. (2015) · Journal of Hospital Medicine · doi:10.1002/jhm.2479 · Cited by 6
Caffrey Morrill, H. J. (2015) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000176 · Cited by 6
“Obese patients treated with vancomycin may be less likely to achieve optimal dosing, which puts patients at risk for poor outcomes [40], even if they had a favorable vancomycin susceptibility.”
BackgroundCost comparison of AUC:MIC– versus trough-based vancomycin monitoring for MRSA bacteremia
Beccari, M. V., Seabury, R. W., Mogle, B. T., Kufel, W. D., Miller, C. D., & Steele, J. M. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.02.025 · Cited by 6
Gibson, A., Kaplan, S. L., & Vallejo, J. G. (2018) · Pediatric Neurosurgery · doi:10.1159/000488498 · Cited by 6
Yoon, J. G., Huh, K., Sohn, Y. M., Park, H. J., Na, S. J., & Jeon, K. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2243 · Cited by 6
“The most accurate PK/PD indicator for effective bacterial killing by vancomycin is known to be an area under the curve (AUC) to minimum inhibitory concentration (MIC), as AUC/MIC ≥400 has been shown to be associated with better clinical outcomes (7,8).”
BackgroundInfluentialPhillips, C. J. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614523819 · Cited by 6
Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Commentary
Hamberg, A., & Keizer, R. J. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000390 · Cited by 6
Kamlungmak, S., Wonglapsuwan, M., Surachat, K., Deachamag, P., & Srichana, T. (2022) · Applied Microbiology · doi:10.3390/applmicrobiol2010019 · Cited by 5
“MRSA bacteremia may be treated with common topical antibiotics, such as silver sulfadiazine, neomycin, bacitracin, and mupirocin [4,5].”
BackgroundIida, M., Horita, Y., Asaoka, M., Ohashi, K., Noda, M., Wachino, C., Hirose, T., Nomura, Y., Hisada, Y., Nagamizu, M., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae249 · Cited by 5
Opinion: The Pharmacometrics of Infectious Disease
Davies, G., Hope, W. W., & Khoo, S. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.46 · Cited by 5
Han, J., Bilker, W. B., Edelstein, P. H., Mascitti, K. B., & Lautenbach, E. (2012) · Epidemiology and Infection · doi:10.1017/s0950268812000295 · Cited by 5
Antimicrobial Stewardship Management of Infections: Beyond the Costs of Antimicrobials
Goff, D. A., Bauer, K. A. A., & Mangino, J. E. (2012) · Cited by 6
Barberán, J., Mensa, J., Artero, A., Epelde, F., Rodriguez, J. C., Ruiz‐Morales, J., Calleja, J. L., Guerra, J.-M., Martínez-Gil, I., Giménez, M.-J., et al. (2019) · Europe PMC (PubMed Central) · Cited by 5
Leven, C., Padelli, M., Chauvet, J., Foulquier, J.-B., Carré, J., & Boglione‐Kerrien, C. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1073 · Cited by 5
Chen, C., Xu, P., Xu, T., Zhou, K., & Zhu, S. (2020) · British Journal of Neurosurgery · doi:10.1080/02688697.2020.1769023 · Cited by 5
“9) Route of VCM administration before TDM ivvp 115 (75) ivgtt 39 (25) Concomitant medication Piperacillin 42 (27) Meropenem 33 (21) Cefoperazone 19 (12) Diuretics 93 (60) Albumin 92 (60) DXM 25 (16) Duration of VCM therapy (day) (median [IQR]) 9 (7-12) Time of blood sampling for TDM (day) (median [IQR]) 4.”
BackgroundClaeys, K. C., Brade, K. D., Heil, E. L., Jorgensen, S. C. J., Dresser, L., & Dalton, B. (2020) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v73i3.3003 · Cited by 7
Introduction to Pharmacodynamics
Craig, W. A. (2013) · Springer eBooks · doi:10.1007/978-0-387-75613-4_1 · Cited by 8
Gram-positive Bacterial Infections
Behera, S. (2018) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/14182_4 · Cited by 5
Johnston, M., Huang, V., Hall, S. T., Buckley, M. S., Bikin, D. S., & Barletta, J. F. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115442 · Cited by 5
Monitoreo terapéutico de vancomicina intravenosa en una unidad de paciente crítico pediátrico
Villena, R., González, C. A., Nalegach, M. E., Vásquez, A., Villareal, M., & Drago, M. (2014) · Revista chilena de infectología · doi:10.4067/s0716-10182014000300001 · Cited by 5
Bubalo, J. S., Kullar, R., & Maziarz, R. T. (2013) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936113504090 · Cited by 5
“…to the emergence of antimicrobial resistance associated with its usage and high treatment failures noted, with prior vancomycin exposure, older age, and certain underlying disease states as independent predictors of vancomycin failure [Khatib et al. 2006; Kullar et al. 2011; Soriano et al. 2008].”
BackgroundSelf-citationLower Vancomycin Serum Trough Concentrations Might Not Be the Answer
Hahn, A., & Vinks, A. A. T. M. M. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000003 · Cited by 5
Jung, D., Kishk, O. A., Bhutta, A. T., Cummings, G. E., Sahly, H. M. E., Virk, M., Moffett, B. S., Morris, J. L., Watanabe, A., Fishbane, N., et al. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001159 · Cited by 4
“Hahn et al (33) could not establish a relationship between AUC 24 /MIC and treatment failure in children, while the association was confirmed in adults (37–40).”
Downes, K. J., Sharova, A. P., Malone, J., John, A. R. O., Zuppa, A. F., & Neely, M. N. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001293 · Cited by 5
Impact of a 20 mg/kg vancomycin loading dose on early AUC target attainment
Yang, S., Antoniello, A., & Smoke, S. M. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116355 · Cited by 4
(SRLF), S. D. R. D. L. F., (Sfar), S. F. D.-R., & Bretonnière, C. (2015) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2015.06.001 · Cited by 5
Fakultas Farmasi, U. S., Setiawan, E., Widyati, Rumah Sakit TNI Angkatan Laut dr. Ramelan, S., Marpaung, F. R., Airlangga, D. P. K. R. D. S. K. U., Rumah Sakit PHC, S., Sukandar, E., Rumah Sakit Umum Moh. Dr. Soewandhie, S., Susaniwati, et al. (2019) · Pharmaceutical Sciences and Research · doi:10.7454/psr.v6i1.4274 · Cited by 4
Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?
Revolinski, S., & Doern, C. D. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00239-21 · Cited by 4
“400, some patients are able to achieve this ratio at lower troughs (8).”
BackgroundRen, J., Hou, Y., Li, J., Gao, Y., Li, R., Jin, X., Zhang, J., Wang, X., & Wang, G. (2021) · Clinical and Translational Science · doi:10.1111/cts.13020 · Cited by 4
Impact of decreasing vancomycin exposure on acute kidney injury in stem cell transplant recipients
Hambrick, H. R., Greco, K. F., Weller, E. A., Ganapathi, L., Lehmann, L., & Sandora, T. J. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.454 · Cited by 4
Slater, J., Stilling, M., Hanberg, P., Vittrup, S., Knudsen, M., Tøstesen, S. K., Kipp, J. O., & Bue, M. (2023) · Antibiotics · doi:10.3390/antibiotics12050907 · Cited by 4
“aureus bacteraemia, illustrating a potential insufficiency of the current practice [27].”
BackgroundVancomycin Hydrochloride as a Risk Factor for Acute Kidney Injury: A Retrospective Study
Uekusa, S., Hanai, Y., Hirayama, S., Yokoo, T., Hasegawa, T., Shimoyama, K., Kusano, A., Nishizawa, K., Μatsumoto, T., & Matsuo, K. (2023) · Pharmacology · doi:10.1159/000531511 · Cited by 4
Multidrug-Resistant Gram-Positive Bacterial Infections
Jung, Y., & Kim, H. B. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.5.487 · Cited by 5
“전체 MRSA 균혈증 가운데 17-30%는 감염된 카테터가 원인 병소로 알려졌다[29,30].”
Russo, A., Ceccarelli, G., Bellelli, V., Bianchi, L., Cattaneo, F. M., Gregori, F., Palmarini, V., Marotta, N., Landi, A., Cuzzolino, A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9120889 · Cited by 4
“Vancomycin use in the setting of difficult-to-treat infections, such as endocarditis and osteomyelitis, was associated with a high failure rate [24].”
BackgroundAppropriateness of basing vancomycin dosing on area under the concentration–time curve
Dalton, B., Dersch‐Mills, D., Langevin, A., Sabuda, D. M., Rennert‐May, E., & Greiner, T. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz184 · Cited by 5
Continuous local antibiotic perfusion for deep infection of the foot and ankle
Nakajima, H., Yamaguchi, S., Kimura, S., Horii, M., Mikami, Y., Sasho, T., & Ohtori, S. (2024) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2024.07.011 · Cited by 5
Therapeutic Monitoring of Vancomycin Implemented by Eremomycin ELISA
Galvidis, I. A., Surovoy, Y. A., Sharipov, V. R., Sobolev, P. D., & Burkin, M. A. (2024) · Antibiotics · doi:10.3390/antibiotics13121133 · Cited by 3
Zamoner, W., Cavalcante, R. D. S., Balbi, A. L., & Ponce, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-82587-1 · Cited by 3
Bloomgren, B. J., & Laible, B. R. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190012466895 · Cited by 3
Staphylococcus aureus Bacteremia and Native Valve Endocarditis: The Role of Antimicrobial Therapy
Karchmer, A. W. (2012) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e31824a8bcb · Cited by 4
Optimizing Single-Drug Antibacterial and Antifungal Therapy
Neely, M. N., & Jelliffe, R. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803348-7.00012-5 · Cited by 5
Ferrari, F., Benegni, S., Marinari, E., Haiberger, R., Garisto, C., Rizza, A., Giorni, C., Quattrone, M. G., Arpicco, S., Muntoni, E., et al. (2021) · Perfusion · doi:10.1177/02676591211006828 · Cited by 3
Sherwin, C. M. T., Tran, N. K., Sullivan, K. G., Wead, S., Birnbaum, A. K., Avachat, C., Healy, D. P., & Kagan, R. J. (2022) · Journal of Burn Care & Research · doi:10.1093/jbcr/irac147 · Cited by 3
Niwa, T., Watanabe, T., Suzuki, K., Hayashi, H., Ohta, H., Nakayama, A., Tsuchiya, M., YASUDA, K., Murakami, N., & Itoh, Y. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12341 · Cited by 3
“Furthermore, poorly dosed vancomycin leads to inferior outcomes.(10) Therefore, to encourage the appropriate use of antibiotics targeting MRSA, since August 2011, an Antimicrobial Stewardship Team (AST) actively recommended the appropriate antibiotics targeting MRSA, considering penetration of target tissues, a patien…”
BackgroundEbenezer, V., Balakrishnan, R., & Christopher, P. (2015) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/736 · Cited by 3
Emergency medicine clinical pharmacist's impact on ordering of vancomycin loading doses
Ibarra, F. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.12.015 · Cited by 3
Talaie, H., Mousavizadeh, A., Emami, H., Gachkar, L., Barari, B., & Alijanzadeh, M. H. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i4.7646 · Cited by 5
“Additional factors may include co-ingestion of nephrotoxic agents, duration of therapy, and underlying physiological impairment (15, 19, 23, 24).”
BackgroundHalim, S. V., & Setiawan, E. (2020) · Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) · doi:10.22487/j24428744.2020.v6.i1.15015 · Cited by 3
Patel, N., Stornelli, N. K., Sangiovanni, R. J., Huang, D. B., & Lodise, T. P. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01268-20 · Cited by 3
Hirai, T., Hanada, K., Iwamoto, T., & Itoh, T. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13646 · Cited by 3
“Thus, renal function plays an important role in the accumulation of VCM and is related to the risk of VCM nephrotoxicity: a clinical predictor of the success rate with VCM treatment.(25) Furthermore, we consider that age might provide an additional explanation for VCM overexposure because eGFR has been incorporated in…”
BackgroundTherapeutic Drug Monitoring: More Than Avoiding Toxicity
Stojanova, J., & Luque, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_9 · Cited by 3
Relevance of vancomycin suceptibility on patients outcome infected with Staphylococcus aureus
Alsayed, A. R., Alzihlif, M., & Ramahi, F. J. W. A. (2019) · The International Arabic Journal of Antimicrobial Agents · doi:10.3823/830 · Cited by 5
Sáez, C., Sarriá, C., Vilacosta, I., Olmos, C., López, J., García-Granja, P. E., Fernández, C., Cuevas, C. D. L., Reyes, G., Domínguez, L., et al. (2019) · Medicine · doi:10.1097/md.0000000000016903 · Cited by 3
Reducing acute kidney injury due to vancomycin in trauma patients
Ko, A., Harada, M. Y., Barmparas, G., Jay, J., Sun, B. J., Chen, E., Mehrzadi, D., Patel, B., Mason, R., & Ley, E. J. (2016) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001105 · Cited by 2
Wang, Y., Gao, P., Zhang, H., Chen, Y.-J., Niu, C., Liu, M., Li, S., Xu, Q., & Ye, Q. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100654 · Cited by 2
Tomoyama, A., Kobayashi, N., Choe, H., Ike, H., Yukizawa, Y., Higashihira, S., Takagawa, S., Kumagai, K., & Inaba, Y. (2023) · Cureus · doi:10.7759/cureus.49535 · Cited by 2
Antibiotic dose optimization in critically ill patients
Cotta, M. O., Roberts, J. A., & Lipman, J. (2015) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2015.07.001 · Cited by 3
Trouillet, J. L., & Chastre, J. E. (2013) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2013.04.003 · Cited by 2
Barberán, J., Varona, J. F., & Tejeda, M. I. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70803-0 · Cited by 2
Lash, D. B., Joson, J., & Heidari, A. (2015) · Case Reports in Infectious Diseases · doi:10.1155/2015/175810 · Cited by 3
Methicillin-Resistant Staphylococcus aureus: A Review of Current Antibiotic Therapy
Snider, J. D., Rivard, B. M., & Specialist, P. (2012) · Cited by 4
Gram-Positive Bacterial Infections After Haematopoietic Stem Cell or Solid Organ Transplantation
Mikulska, M., & Viscoli, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-28797-3_20 · Cited by 2
Antibiotic and Antifungal Therapy in the ICU
Daley, M. J., Hodge, E. K., & Rose, D. T. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-71712-8_36 · Cited by 3
Prokofiev, A. B., Белков, С. А., Kazakov, R. E., Георгиевна, Б. Н., Родина, Т. А., Melnikov, E. S., Danko, A., Voronova, N. E., Vafina, R. Z., Zavtonev, A. V., et al. (2022) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2022-10-2-139-150 · Cited by 2
Bhat, K. G., Kumari, J., Shenoy, S. M., Mahabala, C., & Vidyalakshmi, K. (2016) · Asian Journal of Pharmaceutical and Clinical Research · Cited by 2
Suarez, J. F., Onguti, S. K., & Holubar, M. K. (2021) · Faculty Reviews · doi:10.12703/r/10-66 · Cited by 2
Clinical Pharmacokinetic Principles and Therapeutic Drug Monitoring
Usman, M., Rasheed, H., Maqsood, S., Awan, A. R., & Ali, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812735-3.00402-7 · Cited by 2
Sato, Y., Suzuki, Y., Tanaka, R., Kaneko, T., & Itoh, H. (2019) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00213-3 · Cited by 1
Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections
Kim, S., Lee, S.-Y., & Kang, C.-I. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.463 · Cited by 1
“aureus (MRSA) 균혈증 및 폐렴 연구에 서 유래된 것으로 해석에 주의가 필요하다[13,21-24].”
Shi, Y., Yin, Z., Zhang, Q., Yi, L., & Dou, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1377930 · Cited by 2
Holub, L., Karvaly, G., Závorszky, L., Kristóf, K., Tóth, Á., Tóth, K., Lovász, B., Kassa, C., Vásárhelyi, B., Lakatos, B., et al. (2025) · Orvosi Hetilap · doi:10.1556/650.2025.33279 · Cited by 1
Fann, Z. Y., Othman, E., Chong, S. L., & Saffian, S. M. (2025) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2025-004716 · Cited by 1
“20 27 28 However, our findings align with the PROVIDE study, which reported no mortality benefit—but increased nephrotoxicity— when AUC/MIC exceeded optimal thresholds.”
Peng, H., Tang, X. W., Chen, L., Yang, Q., Cai, J., Xie, T., & Xu, D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1715023 · Cited by 2
Ma, B., Li, Z., Xu, H. J., Chen, Y., Fang, Y., & Xie, J. (2026) · Nature Communications · doi:10.1038/s41467-026-71029-3 · Cited by 1
“Tradi-tionalantibiotics like vancomycin, which is often reserved as a last-line defense, have shown treatment failure rates exceeding 50% in MRSA infections 3 .”
Ladines-Lim, J. B., Nemiroff, A., Cressman, L., & David, M. Z. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag354 · Cited by 1
Recommandations de bon usage des glycopeptides et lipoglycopeptides
Jauréguy, F., Wolff, M., Montravers, P., Salmon, D., Cordonnier, C., Brun‐Buisson, C., & Fantin, B. (2012) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2011.10.004 · Cited by 1
González-Abad, M. J., & Sanz, M. A. (2014) · Anales de Pediatría · doi:10.1016/j.anpedi.2014.07.010 · Cited by 1
Meticillin-resistant Staphylococcus aureus pneumonia
Edwards, B., & Gould, I. (2012) · British Journal of Hospital Medicine · doi:10.12968/hmed.2012.73.7.386 · Cited by 1
Ramahi, J. W. A., Yacoub, A. F., & Shanab, L. A. (2015) · The International Arabic Journal of Antimicrobial Agents · doi:10.3823/769
“Higher failure rates were also reported with “creped” vancomycin MIC, though still within susceptibility ranges of ≤ 2 μg/ml; the upper CLSI limit for vancomycin susceptibility [12, 13].”
BackgroundPoretz, D. M., & Rehm, S. J. (2011) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e31821e260a · Cited by 1
“Newer analyses support the recommendations for targeting higher vancomycin trough levels.(21) As trough levels are pushed higher, increased rates of nephrotoxicity may be a concern.”
Background小児患者におけるバンコマイシンのTDM(therapeutic drug monitoring)
利美, 木. (2012) · Organ Biology · doi:10.11378/organbio.19.98 · Cited by 1
Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration
Arora, H. S., Gupta, S., Sutton, J. D., Abdel‐Haq, N., & Molloy, L. M. (2015) · Journal of Pediatric Intensive Care · doi:10.1055/s-0035-1556751 · Cited by 2
Valbuena, V., Bai, A. D., Showier, A., Meem, M., Steinberg, M., Bell, C. M., & Morris, A. M. (2018) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi.2017-0014 · Cited by 1
Okamoto, G., FURUYA, E., Hirose, S., Hamada, H., & Kobayashi, E. (2020) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.35.151 · Cited by 1
Hasegawa, S., Yashima, H., Takahashi, E., Takahashi, Y., Yamamoto, K., & Obayashi, K. (2020) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.46.387 · Cited by 1
Ogawa, A., Hira, D., Tsujimoto, M., Nishiguchi, K., Endo, M., Ono, T., Hatta, T., Terada, T., & Morita, S. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000920 · Cited by 1
Alraey, Y., Assiry, M. M., Ahmad, I. S., Rab, S. O., Alqahtani, A., Bawazeer, A. O. S., Hussien, T. M. A., Khaja, A. S. S., & Saleem, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04218-4 · Cited by 2
“An international investigation between the USA and Europe showed that MRSA strains developed higher vancomycin MICs, which raises doubts about therapeutic sensitivity while remaining within the MIC breakpoint limits (Kullar et al. 2011).”
Zanotto, M. B., Wappler, P. R., d’Azevedo, P. A., Carneiro, M., Rauber, J. D. M., & Valim, A. R. D. M. (2014) · Revista Jovens Pesquisadores · doi:10.17058/rjp.v4i3.4589 · Cited by 1
Pharmacodynamic Considerations and Special Populations: Pediatrics
Lê, J., & Bradley, J. S. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_22 · Cited by 1
Impact of Higher Vancomycin Troughs on Vancomycin-Induced Nephrotoxicity
Bulloch, M. N., Paumen, L., Eure, S., & Stewart, J. G. (2017) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000496 · Cited by 1
Lazareva, N. B., Ших, Е. В., Drozdov, V. N., & Rebrova, E. V. (2018) · Вопросы современной педиатрии · doi:10.15690/vsp.v17i1.1855 · Cited by 1
“У взрослых пациентов при инфекциях, вызванных MRSA, достижение значения AUC0–24/МПК > 400 ассоциируется с достижением благоприятного клинического исхода заболевания по сравнению с пациентами, у которых соотношение AUC0–24/МПК составляет менее 400 [44].”
バンコマイシン TDM 解析ソフト TOWA-TDM と MEEK との予測性およびベイジアン収束性の比較評価
司, 関., 匠, 野., 田島, 正., 菜緒, 田., 杉山, 恵., & 均, 佐. (2021) · doi:10.11256/jjdi.23.17 · Cited by 1
Perrine, J. A., Bennett, K. K., Siegrist, E. A., Bradford, C. V., & Schwier, N. C. (2023) · Journal of Pharmacy Technology · doi:10.1177/87551225221149732 · Cited by 1
Joson, J., Grover, C. A., Downer, C., Pujar, T., & Heidari, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr401 · Cited by 1
Long, V. (2014) · Loyola eCommons (Loyola University of Chicago)
Metadata
- Authors
- Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 52
- Issue
- 8
- Pages
- 975-981
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099365065
- Semantic Scholar
- ed3c7f78a7e345dd4578c14051be67b5da32fd88
- Cited by
- 463
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 22 · 2021: 37 · 2020: 33 · 2019: 40 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 37 · 2014: 43 · 2013: 57 · 2012: 45
- FWCI
- 34.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, methicillin-resistant Staphylococcus aureus, MRSA bacteremia, pharmacokinetic/pharmacodynamic targets, AUC/MIC ratio, trough concentration, infective endocarditis, nosocomial infections, antimicrobial susceptibility testing, E-test, broth microdilution
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Bacteremia, Treatment Outcome, Guidelines as Topic, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.